Attrition of Patients on a Precision Oncology Trial: Analysis of the I-PREDICT Experience.

Sandy S BohanJason K SicklickShumei KatoRyosuke OkamuraVincent A MillerBrian Leyland-JonesScott M LippmanRazelle Kurzrock

Published in: The oncologist (2020)

Health deterioration of consented patients is a significant barrier to being evaluable on the I-PREDICT trial. These data suggest that patients are enrolled on precision oncology trials too late in their disease course or with excessive disease burden.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
healthcare
prognostic factors
clinical trial
public health
study protocol
machine learning
phase iii
artificial intelligence